Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 1

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 200,000,000 shares authorized, 673,320 and 610,389 shares issued and outstanding as of June
    30, 2025 and December 31, 2024, respectively

    67

    61

    Additional paid
    in capital

    20,397,175

    18,760,872

    Accumulated deficit

    (26,891,537
    )

    (21,474,987
    )

    TOTAL STOCKHOLDERS’
    DEFICIT

    (6,494,295
    )

    (2,714,054
    )

    TOTAL LIABILITIES
    AND STOCKHOLDERS’ DEFICIT
     
    $
    822,850

    $
    1,369,143

The
accompanying notes are an integral part of these condensed consolidated financial statements.

1 

 PELTHOS THERAPEUTICS INC. 

CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS

FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Unaudited)

    For
    the Three months Ended June 30, 

    For
    the Six months Ended June 30,

    2025

    2024

    2025

    2024

    OPERATING EXPENSES

    General and administrative expenses
    $
    1,110,084

    $
    1,209,874

    $
    2,200,133

    $
    1,997,435

    Research and development
     
    514,814

    12,955

    709,112

    479,561

    Professional fees
     
    1,605,525

    541,257

    2,155,155

    1,221,072

    Total operating expenses
     
    3,230,423

    1,764,086

    5,064,400

    3,698,068

    NET LOSS FROM OPERATIONS
     
    (3,230,423
    )

    (1,764,086
    )

    (5,064,400
    )

    (3,698,068
    )

    OTHER EXPENSE

    Interest expense
     
    (